| http://dbpedia.org/ontology/abstract
|
NNI-351 is an orally active inhibitor of D … NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. yet to progress to human clinical trials.
|
| http://dbpedia.org/ontology/casNumber
|
929607-23-8
|
| http://dbpedia.org/ontology/fdaUniiCode
|
97LG4X5P2E
|
| http://dbpedia.org/ontology/pubchem
|
16661882
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/NNI-351.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.neuronascent.com/r&d-downs.htm +
, https://www.google.com/patents/US20120277218 +
, http://adisinsight.springer.com/drugs/800029097 +
|
| http://dbpedia.org/ontology/wikiPageID
|
54219225
|
| http://dbpedia.org/ontology/wikiPageLength
|
3249
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1108113534
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Neurogenesis +
, http://dbpedia.org/resource/Category:Nitriles +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/Category:Experimental_drugs +
, http://dbpedia.org/resource/Category:Thioketones +
, http://dbpedia.org/resource/Category:Fluoroarenes +
, http://dbpedia.org/resource/Category:Quinolines +
, http://dbpedia.org/resource/Preclinical_development +
, http://dbpedia.org/resource/Down_syndrome +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Category:Ethers +
, http://dbpedia.org/resource/Category:Diazepanes +
, http://dbpedia.org/resource/List_of_investigational_antidepressants +
, http://dbpedia.org/resource/Category:Thioamides +
, http://dbpedia.org/resource/Post-traumatic_stress_disorder +
, http://dbpedia.org/resource/Enzyme_inhibitor +
, http://dbpedia.org/resource/Depression_%28mood%29 +
|
| http://dbpedia.org/property/c
|
24
|
| http://dbpedia.org/property/casNumber
|
929607
|
| http://dbpedia.org/property/chemspiderid
|
17594951
|
| http://dbpedia.org/property/f
|
1
|
| http://dbpedia.org/property/h
|
24
|
| http://dbpedia.org/property/iupacName
|
4
|
| http://dbpedia.org/property/n
|
5
|
| http://dbpedia.org/property/o
|
1
|
| http://dbpedia.org/property/pubchem
|
16661882
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/s
|
1
|
| http://dbpedia.org/property/smiles
|
CCOC1=CC2=CN=CN3CCCNCNC4=CC=CC=C4F
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
RQXUPDSAFGWKMO-UHFFFAOYSA-N
|
| http://dbpedia.org/property/unii
|
97
|
| http://dbpedia.org/property/width
|
250
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Nervous-system-drug-stub +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Abbrlink +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Ethers +
, http://dbpedia.org/resource/Category:Thioamides +
, http://dbpedia.org/resource/Category:Nitriles +
, http://dbpedia.org/resource/Category:Fluoroarenes +
, http://dbpedia.org/resource/Category:Quinolines +
, http://dbpedia.org/resource/Category:Thioketones +
, http://dbpedia.org/resource/Category:Diazepanes +
, http://dbpedia.org/resource/Category:Experimental_drugs +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/NNI-351?oldid=1108113534&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/NNI-351.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/NNI-351 +
|
| owl:sameAs |
http://www.wikidata.org/entity/Q30315125 +
, http://dbpedia.org/resource/NNI-351 +
, https://global.dbpedia.org/id/2owdX +
|
| rdf:type |
http://www.wikidata.org/entity/Q8386 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/ontology/Drug +
|
| rdfs:comment |
NNI-351 is an orally active inhibitor of D … NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. yet to progress to human clinical trials.
|
| rdfs:label |
NNI-351
|
